PPCB · XBRL financial data
Propanc Biopharma financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (PPCB's year ends in late June)
| In thousands of dollars | Jun 30, 2021 | †Jun 30, 2022 | †Jun 30, 2023 | †Jun 30, 2024 | †Jun 30, 2025 | †Jun 30, 2026 |
|---|---|---|---|---|---|---|
| Research and development | 231 | 256 | 248 | 248 | 224 | 625 |
| General and administrative | 1,553 | 1,706 | 1,500 | 1,254 | 57,028 | 671 |
| Total operating expenses | 1,812 | 1,991 | 1,777 | 1,536 | 57,278 | 18,186 |
| Operating income (loss) | (1,812) | (1,991) | (1,777) | (1,536) | (57,278) | (18,186) |
| Interest income | 0 | 6 | — | — | — | — |
| Interest expense | 449 | 569 | 533 | 666 | 564 | 431 |
| Other income (expense) | — | — | — | — | — | (6) |
| Income tax expense (benefit) | (113) | (55) | (130) | (129) | — | — |
| Net income (loss) | (2,418) | (2,658) | (2,661) | (1,821) | (58,923) | (18,863) |
| Earnings per share, basic USD per share | (0.80) | (0.05) | (1.80) | (0.02) | (14.85) | (17.62) |
| Earnings per share, diluted USD per share | — | (49.23) | (1.80) | (0.02) | (14.85) | (17.62) |
| Weighted average shares, basic thousands of shares | 3,033 | 68,219 | 1,739 | 85,045 | 3,968 | 1,124 |
| Weighted average shares, diluted thousands of shares | — | 68 | 1,739 | 85,045 | 3,968 | 1,124 |
- † Share count changed about 16x in the period ending 2022-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/46 in the period ending 2023-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 46x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/54 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/2 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (PPCB's year ends in late June)
| In thousands of dollars | Jun 30, 2021 | †Jun 30, 2022 | †Jun 30, 2023 | †Jun 30, 2024 | †Jun 30, 2025 | †Jun 30, 2026 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 2 | 4 | 10 | 21 | 12 | 832 |
| Prepaid and other current assets | — | 9 | 6 | 1 | — | — |
| Total current assets | 7 | 15 | 19 | 25 | 8,353 | 8,543 |
| Property and equipment, net | 4 | 2 | 0 | — | — | 4 |
| Right-of-use asset | — | 63 | — | 18 | 59 | 41 |
| Total assets | 13 | 82 | 60 | 72 | 19,632 | 12,780 |
| Accounts payable | 1,002 | 943 | 967 | 1,213 | 1,250 | 1,131 |
| Total current liabilities | 3,081 | 3,063 | 3,158 | 3,793 | 5,578 | 3,354 |
| Lease liability, non-current | — | 42 | — | — | 42 | 24 |
| Total liabilities | 3,081 | 3,105 | 3,178 | 3,851 | 5,726 | 3,378 |
| Accumulated deficit | (58,199) | (61,558) | (64,685) | (66,698) | (125,622) | (144,484) |
| Total stockholders' equity | (3,068) | (3,024) | (3,117) | (3,779) | 13,906 | 9,402 |
| Total liabilities and equity | 13 | 82 | 60 | 72 | 19,632 | 12,780 |
| Common shares outstanding (cover page) thousands of shares | 41,099 | 677,178 | 14,833 | 688,022 | 12,807 | 6,331 |
- † Share count changed about 16x in the period ending 2022-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/46 in the period ending 2023-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 46x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/54 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/2 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (PPCB's year ends in late June)
| In thousands of dollars | Jun 30, 2021 | †Jun 30, 2022 | †Jun 30, 2023 | †Jun 30, 2024 | †Jun 30, 2025 | †Jun 30, 2026 |
|---|---|---|---|---|---|---|
| Net income (loss) | (2,418) | (2,658) | (2,661) | (1,821) | (58,923) | (18,863) |
| Stock-based compensation | 83 | 73 | 2 | — | 4,621 | 8,498 |
| Net cash from operating activities | (1,145) | (1,436) | (1,105) | (935) | (405) | (5,683) |
| Purchases of property and equipment | — | — | — | — | — | 5 |
| Net cash from investing activities | — | — | — | — | — | (5) |
| Proceeds from issuing common stock | — | 99 | 25 | 23 | — | 3,314 |
| Net cash from financing activities | 1,058 | 1,491 | 1,114 | 942 | 491 | 6,457 |
| Net change in cash | (65) | 2 | 6 | 11 | (9) | 820 |
- † Share count changed about 16x in the period ending 2022-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/46 in the period ending 2023-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 46x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/54 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/2 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Propanc Biopharma | 832 | not reported | (1,602)* | 6.3M | 0.5 quarters | 10-KJun 30, 2026 |
| Cannapharmarx | 0.6 | 276 | (127)* | 708.7M | 0.0 quarters | 10-QJun 30, 2026 |
| MetaVia | 12,634 | not reported | (3,762)* | 6.6M | 3.4 quarters | 10-QJun 30, 2026 |
| Oragenics | 3,864 | not reported | (2,187)* | 4.5M | 1.8 quarters | 10-QJun 30, 2026 |
| Inhibitor Therapeutics | 516 | not reported | (775)* | 173.8M | 0.7 quarters | 10-QJun 30, 2026 |
| PTC Therapeutics | 508,894 | 357,807 | (25,311)* | 83.5M | — | 10-QSep 30, 2026 |
| Integrated Biopharma | 4,471 | not reported | (1,194)* | 31.1M | 3.7 quarters | 10-KJun 30, 2026 |
| Nomad Power Solutions | 12,670 | not reported | (1,612)* | 16.1M | 7.9 quarters | 10-QJun 30, 2026 |
| Enveric Biosciences | 8,296 | not reported | (2,445)* | 4.5M | 3.4 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.